Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Caspofungin in Japanese Pediatric Patients With Candida or Aspergillus Infections
2014-004910-27Phase 2
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in invasive candidiasis, Candida esophagitis, aspergillosis and 1 more, sponsored by Merck & Co. Primary endpoint: Safety and tolerability of caspofungin.
02
Drugs
caspofungin
03
Conditions
invasive candidiasisCandida esophagitisaspergillosiscandidiasis
Beyond the preview
Go deeper on 2014-004910-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004910-27.